novo semaglutide alzheimer's Details of failed studies cast pall on Nordisk's GLP-1 as treatment Novo Nordisk Alzheimer's drug trials

Blood sugar spikes

Eur.J.Gen.Med 2009;6(2):7-15

That is why a medically guided program includes nutrition, lifestyle coaching, and a thoughtful tapering plan

doi: 10.1007/s13105-014-0333-4

When additional therapy is required, NICE recommends considering a GLP-1 receptor agonist (such as Rybelsus) if the patient has a BMI of 35 kg/m or higher (or 32.5 kg/m or higher for people of South Asian or related ethnicity) and specific psychological or medical problems associated with obesity, or if BMI is lower but insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities